Skip to main content
. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103

Table 1. Clinical features of the cohort at the time of the index event.

Male/female, N (%) 63/118 (34.8/65.2)
Age, years, median (range) 48 (29–74)
 <40 years, n (%) 51 (28.2)
 40–60 years, n (%) 90 (49.7)
 ⩾60 years, n (%) 40 (22.1)
   
Diagnosis, N (%)
 PV 67 (37.0)
 ET 67 (37.0)
 PMF 47 (26.0)
Years from diagnosis to index thrombosis, mean (±s.d.) 2.01 (3.87)
Diagnosis at the time of index thrombosis, n (%) 105 (58)
   
Hb gr/dl, median (range) 13.4 (6.3–24.0)
Hct %, median (range) 42.1 (22.0–70.0)
WBC count × 109/l, median (range) 9.3 (3.0–50.0)
Platelet count × 109/l, median (range) 424 (100–3000)
   
JAK2 mutation, N/N tested (%) 166/178 (93.3)
 CALR mutations, N/N tested 4/25 (16.0)
 MPL mutations, N/N tested 1/28 (3.6)
 Exon 12 mutations, N/N tested 0/14 (0.0)
   
Abnormal karyotype, N/N tested (%) 8/65 (12.3)
Microvascular disturbances, N (%) 19 (10.5)
Constitutional symptoms, N (%) 28 (15.5)
Palpable splenomegaly, N (%) 119 (65.8)
Cm below costal margin, median (range) 4 (1–25)
   
Localization of index thrombosis, N (%)
 Hepatic vein thrombosis (BCS) 31 (17.1)
 Portal vein thrombosis 109 (60.3)
 Mesenteric vein thrombosis 18 (9.9)
 Splenic vein thrombosis 23 (12.7)
   
Unprovoked thrombosis, N (%) 155 (85.6)
 Provoked by, n (%) 26 (14.4)
  Oral contraceptives 8 (4.4)
  Hormone replacement therapy 3 (1.7)
  Infection 3 (1.7)
  Pregnancy/puerperium 1 (0.6)
  Cancer 1 (0.6)
  Surgery 7 (3.9)
  Liver disease 3 (1.7)
   
Risk factors for index thrombosis
 History of thrombosis, N (%) 14 (7.7)
  History of arterial thrombosis, n (%) 5 (2.8)
  History of venous thrombosis, n (%) 8 (4.4)
 Presence of at least one vascular risk factor, N (%) 52 (28.7)
  Smoking habit 19 (10.5)
  Hypertension 28 (15.5)
  Dislipidemia 7 (3.4)
  Diabetes 5 (2.8)
 Presence of thrombophilia*, N/N tested (%) 42/120 (35.0)
  Inherited thrombophilia, N/N tested (%) 21/120 (17.5)

Abbreviations: BCS, Budd Chiari syndrome; ET, essential thrombocythaemia; Hb, haemoglobin; PMF, primary myelofibrosis; PV, polycythaemia vera; WBC, white blood cell.

Deficiency of antitrombin (n=1), deficiency of protein C or protein S (n=7), factor V Leiden and/or prothrombin G20210A (n=13), increased levels of homocysteine (n=16), antiphospholipids (n=6).